On 26 October 2018, orphan designation (EU/3/18/2072) was granted by the European Commission to FGK Representative Service GmbH, Germany, for 6-(R)-methyl-5-O-(5-amino-5,6-dideoxy-alpha-L-talofuranosyl)-paromamine sulfate (also known as ELX-02) for the treatment of cystic fibrosis.
|Disease / condition||
Treatment of cystic fibrosis
|Date of decision||
|Orphan decision number||
Review of designation
Sponsor's contact details
For contact details of patients’ organisations whose activities are targeted at rare diseases, see:
European Organisation for Rare Diseases (EURORDIS), a non-governmental alliance of patient organisations and individuals active in the field of rare diseases.
- Orphanet, a database containing information on rare diseases, which includes a directory of patients’ organisations registered in Europe;